Lyra Therapeutics Inc (NAS:LYRA)
$ 0.2952 -0.0149 (-4.8%) Market Cap: 18.00 Mil Enterprise Value: -31.26 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 29/100

Lyra Therapeutics Inc at HC Wainwright Investment Conference - New York Transcript

Sep 13, 2023 / 06:00PM GMT
Release Date Price: $4.69 (+1.96%)
Matthew Caufield
H.C. Wainwright - Analyst

All right. Welcome back, everyone, to H.C. Wainwright's 25th Annual Global Investment Conference. My name is Matthew Caufield. I'm a biotechnology equity research analyst here at HCW.

We're very pleased to now have a fireside chat with Lyra Therapeutics, and I'd like to welcome President and CEO Maria Palasis. Thank you very much for being here.

Maria Palasis
Lyra Therapeutics, Inc. - President & CEO

Thank you, Matthew. It's great to be here.

Questions & Answers

Matthew Caufield;Maria Palasis
H.C. Wainwright - Analyst

Excellent. Well, we're very excited. Obviously, the team recently had their Phase 2 positive top line for the BEACON trial for candidate LYR-220 in post-surgical CRS. So maybe just before we dive into that topic and kind of all the progress you guys have been up to, maybe just, at a high level, you could tell us a little bit about your company's strategic focus, sort of your disease focus, the unmet need.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot